ReviewCurrent oncology reports2026
PET Imaging in Head and Neck Squamous Cell Carcinoma: from Staging to Response Assessment.
Review in Current oncology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of review¹⁸F-fluorodeoxyglucose positron emission tomography/computed tomography (¹⁸F-FDG PET/CT) has become a cornerstone in the management of head and neck squamous cell carcinoma (HNSCC). While conventional imaging defines anatomical extent, PET provides complementary metabolic information crucial for staging, prognostication, treatment adaptation, and surveillance. This review aims to synthesize current evidence on the role of PET imaging in HNSCC, integrating recent data on quantitative biomarkers, novel radiotracers, and artificial intelligence (AI)–based analytical approaches. RECENT
findingsPET/CT demonstrates superior sensitivity for nodal and distant metastases compared with CT or MRI, particularly in advanced-stage or unknown-primary disease. Quantitative metrics such as SUVmax, metabolic tumor volume, and total lesion glycolysis provide independent prognostic value beyond TNM staging. In the post-treatment setting, ¹⁸F-FDG PET/CT reliably identifies complete metabolic response, reducing unnecessary neck dissections. Limitations include false positives early after therapy due to inflammation or osteoradionecrosis; dual-timepoint acquisition and PET/MRI may enhance specificity. New tracers targeting hypoxia (¹⁸F-FMISO), proliferation (¹⁸F-FLT), angiogenesis (⁶⁸Ga-RGD), and cancer-associated fibroblasts (⁶⁸Ga-FAPI) show promise for biological target delineation. AI methods, including radiomics and deep learning, have demonstrated potential for automated nodal detection and outcome prediction, though clinical validation remains limited. ¹⁸F-FDG PET/CT, complemented by emerging molecular tracers and AI-driven analysis, represents a pivotal tool for personalized management of HNSCC. By integrating anatomical, metabolic, and biological information, PET imaging supports refined staging, individualized radiotherapy planning, and improved patient outcomes.
Indexed as
Identifiers
41661435What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.